Dignitana has signed a Distribution Agreement for Boosst to be the exclusive provider of The DigniCap Scalp Cooling System in Ecuador and Peru. Initiating the agreement, Boosst has purchased two DigniCap Delta devices which will be delivered this month and used at Life & Hope Specialty Care in Quito. DigniCap is an innovative medical device used by cancer centers to minimize hair loss from chemotherapy.

Christian Frison, CEO of Boosst,  said, "I am excited to offer this cutting-edge technology to cancer centers, giving patients a way to maintain dignity and quality of life during chemotherapy treatment. DigniCap provides a unique opportunity in Ecuador and Peru, and we see a strong demand for the product."

Frison has extensive MedTech experience in South America, having previously run  an automated healthcare diagnostics company and subsequently selling it to one of Ecuador's largest companies.

"Dignitana is focused on increasing availability of the DigniCap technology to patients around the globe. This agreement expands our reach in a largely untapped market in South America, and we value the expertise and extensive healthcare network that Boosst will leverage," said Fredrik Jonsson, Dignitana CEO.

The FDA-cleared DigniCap Delta device uses industry-leading thermoelectric cooling to minimize hair loss that is a side effect of chemotherapy prescribed to treat solid tumors such as those from breast cancer, ovarian cancer and prostate cancer. Recognized internationally as a standard of care and quality of life advancement for cancer patients, scalp cooling is a treatment recommendation in the clinical practice guidelines published by National Comprehensive Cancer Network® (NCCN), European Society for Medical Oncology (ESMO), and Cancer Australia. It is available in cancer centers around the globe.

Breast cancer is the most prevalent cancer in Ecuador, with approximately 3,900 new cases diagnosed in 2022, making it the most common cancer type among newly diagnosed patients in the country. In Peru, breast cancer is the second most common cancer diagnosed, with approximately 7,800 new cases reported in 2022. (statista.com)